Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
04 June 2024 - 10:05PM
Business Wire
- Upgraded gene panel on tissue genomic profiling test covers 498
biomarkers, including guideline-recommended genes
- Operational improvements streamline workflow and shorten time
to results
- Upgraded test covered by Medicare for comprehensive genomic
profiling of all advanced solid tumors
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology
company, today announced the launch of a new version of its
Guardant360 TissueNext test that expands the number of genes it
identifies in a tumor tissue sample to 498. These genes, or cancer
biomarkers, enable oncologists to identify the targeted therapies
or treatment strategies that are most effective for patients with
advanced cancer. In addition to the panel expansion, Guardant has
improved the test’s operational workflow for a faster turnaround
time.
The new Guardant360 TissueNext test will be covered for Medicare
fee-for-service patients with advanced solid tumor cancers as a
standalone service, based on coverage conveyed by Palmetto GBA, a
Medicare administrative contractor for the Molecular Diagnostics
Services program (MolDX®), under the existing local coverage
determination.
“The launch of the new Guardant360 TissueNext test is another
step forward in our mission to conquer cancer with data,” said
Helmy Eltouky, Guardant Health chairman and co-CEO. “In addition to
identifying guideline-recommended biomarkers, the upgraded test now
provides more comprehensive gene coverage, so oncologists can make
better informed decisions about the optimal treatment strategy for
their patients with advanced cancer and help improve their
outcomes.”
Guardant360 TissueNext identifies clinically relevant actionable
biomarkers in tumor tissue to help oncologists select patients with
advanced cancer who may benefit from biomarker-informed treatment.
Results are provided in less than two weeks.
The test, which first received Medicare coverage in March 2022,
is part of Guardant’s comprehensive portfolio of blood- and
tissue-based genomic profiling tests, including Guardant360 CDx,
the first liquid biopsy test approved by the FDA for comprehensive
genomic profiling of all solid tumors. The Guardant360 TissueNext
test can be ordered alone or in combination with Guardant360 CDx to
support guideline-recommended complementary liquid and tissue
genomic profiling testing for advanced breast and lung cancer.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on guarding wellness and giving every person more time free from
cancer. Founded in 2012, Guardant is transforming patient care by
providing critical insights into what drives disease through its
advanced blood and tissue tests, real-world data and AI analytics.
Guardant tests help improve outcomes across all stages of care,
including screening to find cancer early, monitoring for recurrence
in early-stage cancer, and helping doctors select the best
treatment for patients with advanced cancer. For more information,
visit guardanthealth.com and follow the company on LinkedIn, X
(Twitter) and Facebook.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of federal securities laws, including statements regarding
the potential utilities, values, benefits and advantages of
Guardant Health’s liquid biopsy tests or assays, which involve
risks and uncertainties that could cause the actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions, and
actual outcomes and results could differ materially from these
statements due to a number of factors. These and additional risks
and uncertainties that could affect Guardant Health’s financial and
operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
news release include those discussed under the captions “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operation” and elsewhere in its Annual
Report on Form 10-K for the year ended December 31, 2023, and in
its other reports filed with or furnished to the Securities and
Exchange Commission thereafter. The forward-looking statements in
this news release are based on information available to Guardant
Health as of the date hereof, and Guardant Health disclaims any
obligation to update any forward-looking statements provided to
reflect any change in its expectations or any change in events,
conditions, or circumstances on which any such statement is based,
except as required by law. These forward-looking statements should
not be relied upon as representing Guardant Health’s views as of
any date subsequent to the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240604612220/en/
Investor Contact: Zarak Khurshid
investors@guardanthealth.com
Media Contact: Michael Weist press@guardanthealth.com +1
317-371-0035
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From May 2024 to Jun 2024
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From Jun 2023 to Jun 2024